Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Cese de los análogos de la somatostatina después de la PRRT en tumores neuroendocrinos del intestino medio (STOPNET)

9 de noviembre de 2026 actualizado por: Australasian Gastro-Intestinal Trials Group

Un estudio aleatorizado sobre el cese de los análogos de la somatostatina después de la terapia con radionúclidos receptores de péptidos en tumores neuroendocrinos del intestino medio (STOPNET)

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.

The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.

Descripción general del estudio

Descripción detallada

Neuroendocrine tumours commonly originate from the gut and metastasise widely including to the liver, lymph nodes and bones. Originally called "carcinoid tumours", these cancers are most commonly treated with somatostatin analogues (SSA) first line. These analogues treat carcinoid syndrome and slow tumour growth. Despite SSA therapy, progression develops over time. Upon progression, peptide receptor radionuclide therapy (PRRT) is the next standard therapeutic option. After PRRT is initiated, it is unclear if continuing SSA injections is beneficial. There are reasons to believe it might be necessary to continue SSAs, but other reasons to believe they should cease. Given that SSA injections are expensive and associated with side effects, this study aims to clarify the utility of continuing SSA injections after progression on SSA therapy and commencement of PRRT.

STOPNET aims to explore outcomes in grade 1 and 2 mid, hind gut or pancreatic neuroendocrine tumours, that have progressed on SSA therapy, are eligible to receive PRRT and in whom the SSA is either continued or ceased after PRRT is commenced.

The two primary objectives include

  1. To estimate the 20-month progression free survival rate after PRRT commencement in patients who cease and who continue SSA.

  2. Feasibility as measured by:

    1. Recruitment rate and
    2. Patient acceptance of ceasing and staying off SSA over the 20 month follow up period.

The study design of STOPNET is prospective, randomised, non-comparative, open label, multicentre phase II study. Patients meeting the inclusion and exclusion criteria will be randomised, prior to commencing PRRT, to either continue or cease SSA treatment. Randomisation will occur centrally in REDCap by the AGITG STOPNET study team. Randomisation will be 2:1 (the majority being randomised to cease SSA) and will be stratified by WHO tumour grade (1 V 2), sites of metastases (visceral only verse visceral and bone) and institution.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

78

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • New South Wales
      • Sydney, New South Wales, Australia, 2065
        • Reclutamiento
        • Royal North Shore Hospital
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Dr David Chan
      • Wollongong, New South Wales, Australia, 2502
        • Reclutamiento
        • Wollongong Hospital
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Dr Derrick Siu
    • Queensland
      • Brisbane, Queensland, Australia, 4006
        • Reclutamiento
        • Royal Brisbane and Womens Hospital
        • Contacto:
        • Contacto:
        • Investigador principal:
          • A/Prof Matthew Burge
      • Cairns, Queensland, Australia, 4870
        • Reclutamiento
        • Cairns Hospital
        • Contacto:
      • Toowoomba, Queensland, Australia, 4350
        • Reclutamiento
        • Toowoomba Hospital
        • Contacto:
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Reclutamiento
        • The Queen Elizabeth Hospital
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Prof Timothy Price
    • Victoria
      • Melbourne, Victoria, Australia, 3000
        • Reclutamiento
        • Peter MacCallum Cancer Centre
        • Contacto:
        • Investigador principal:
          • Dr Hui-Li Wong
        • Contacto:
    • Western Australia
      • Kalgoorlie-Boulder, Western Australia, Australia, 6430
        • Reclutamiento
        • Kalgoorlie Health Campus
        • Contacto:
      • Perth, Western Australia, Australia, 6150
        • Reclutamiento
        • Fiona Stanley Hospital
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Dr Piyush Grover
    • Alberta
      • Edmonton, Alberta, Canadá, T6G 1Z2
        • Reclutamiento
        • Cross Cancer Institute
        • Contacto:
          • Dr Stella Koumna
          • Número de teléfono: 780-432-8771
          • Correo electrónico: koumna@ualberta.ca
        • Investigador principal:
          • Dr Stella Koumna
    • British Columbia
      • Vancouver, British Columbia, Canadá, V5Z 4E6
        • Reclutamiento
        • BC Cancer Agency, Vancouver Cancer Centre
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Dr Jon Loree
    • Ontario
      • London, Ontario, Canadá, N6A 5W9
        • Reclutamiento
        • London Health Sciences Centre Research Institute (LHSCRI)
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Dr David Laidley
      • Ottawa, Ontario, Canadá, K1Y 1J8
        • Reclutamiento
        • Ottawa Hospital Research Institute
        • Contacto:
          • Dr Rachel Goodwin
          • Número de teléfono: 613-737-8899
          • Correo electrónico: rgoodwin@toh.ca
        • Investigador principal:
          • Dr Rachel Goodwin
      • Toronto, Ontario, Canadá, M5G 2M9
        • Reclutamiento
        • University Health Network Princess Margaret Cancer Centre
        • Contacto:
        • Investigador principal:
          • Dr Raymond Jang
      • Toronto, Ontario, Canadá, TG 260
        • Reclutamiento
        • Odette Cancer Centre Sunnybrook Health Sciences Centre
        • Contacto:
        • Investigador principal:
          • Dr Sten Myrehaug
    • Saskatchewan
      • Regina, Saskatchewan, Canadá, S4T 7T1
        • Reclutamiento
        • Allan Blair Cancer Centre
        • Contacto:
        • Investigador principal:
          • Dr Mussawar Iqbal
      • Saskatoon, Saskatchewan, Canadá, S7N 4H
        • Reclutamiento
        • Saskatoon Cancer Centre
        • Contacto:
        • Investigador principal:
          • Dr Mita Manna

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Adults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour; metastatic and inoperable, demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT as determined by the treating clinician and/or the NET Multidisciplinary Team (MDT). See section 4.1 regarding the recording of the reason(s).

  2. Must have measurable disease on triphasic CT/MRI as per RECIST 1.1.

  3. Ki67 ≤20% AND mitotic count ≤20 per HPF (i.e., WHO grade 1 or 2).

    • Note: Participants are eligible if only a single proliferation index has been performed due to local institutional practice, provided that the results are consistent with WHO grade 1 or 2 NET. However, if the results for both Ki67 and mitotic count are available, both results will need to be reported and are subject to eligibility assessment.

  4. Non-functioning NET: SSA treatment will have been commenced for control of tumour growth and not for carcinoid or other hormone overproduction syndrome, as judged by the clinician and/or NET MDT. Non-functioning NET is judged by the treating clinical team based on patient symptomatology.

    In addition, for this study, non-functioning tumour is defined as:

    • Never had escalation of the SSA treatment dose to control carcinoid or other hormone-related symptoms.

    • Never required short acting SSA treatment to control carcinoid or other hormone-related symptoms.

    • For mid and hind gut (GI cohort) patients:

      • 24-hour urine 5-hydroxyindoleacetic acid (5HIAA) <3x upper limit of normal.
      • No significant carcinoid induced valvular heart disease. I.e. Echocardiogram to be within 12 weeks of study randomisation, and deemed safe to proceed with PRRT by the treating team.
    • Note: routine measurement of gastrin, insulin, C-peptide levels, glucagon etc. is not required unless clinically indicated.

  5. Patient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study enrolment, for example a minimum of 30mg Octreotide or 120mg Lanreotide monthly. However, other SSA formulations used at growth-controlling doses are also eligible.

  6. Uptake on SSTR PET scan demonstrating somatostatin receptor expression that is suitable for PRRT as judged by the clinical team. FDG PET scans are to be done at the judgement of the treating team and are not required for enrolment into this study.

  7. PRRT is deemed the most appropriate next treatment step (i.e., patient is inoperable, and liver directed therapies are not preferred).

  8. ECOG performance status 0-2.

  9. Written informed consent. Patients must be willing to either cease or continue SSA, depending on which study arm they are randomised to. Patients must be willing to comply with all other study requirements.

  10. Adequate renal, hepatic and haematologic function as judged by the treating team.

  11. Life expectancy of at least 12 months.

Exclusion Criteria:

  1. This study is for pancreatic, mid-gut and hind-gut NET only. Gastric and lung NETs are excluded.
  2. Any patient on an SSA dose lower than the standard growth-control dose. Patients must have been on an SSA equivalent to Octreotide 30mg or Lanreotide 120mg for at least 3 months prior to study enrolment.
  3. Prior chemotherapy or targeted therapy (e.g., everolimus). Patients who have received prior local therapy, including external beam radiotherapy and liver directed therapy prior to or during SSA therapy are eligible.
  4. Any contraindication to PRRT, as per local institutional practice.
  5. Pregnancy. For female patients of childbearing potential and male patients with a female partner who is of childbearing potential, contraception and counselling is required.
  6. Prior PRRT. Patients being considered for re-treatment with PRRT are not eligible.
  7. Uncontrolled central nervous system metastases. Patients must have completed any surgery or radiation at least 4 weeks prior to enrolment and must be off corticosteroids for at least 2 weeks.
  8. Any patient, in the opinion of the investigator, who will not comply with study assessments and follow up visits. These might include any social, psychological, or geographical concerns, including alcohol/drug abuse.
  9. Any poorly controlled concurrent medical illness that may prevent the patient from complying with study assessments and follow up. This is to be judged by the treating team.
  10. Any concurrent or prior malignancy that, in the opinion of the treating team, may interfere with study assessments and endpoints.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Continue SSA

Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.

Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.

Otros nombres:
  • Continuación de SSA
Experimental: Cease SSA

Patients randomised to cease SSA will receive SSA injection ≥28 days prior to their first cycle of PRRT. Patients will not receive any further long acting SSA injections after this time.

Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.

Otros nombres:
  • Cese de la SSA

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
20-month progression free survival rate after PRRT
Periodo de tiempo: 20 months

Estimate the 20-month progression free survival rate after PRRT in patients who cease and who continue SSA.

20 months
Assess the barriers which would impede the feasibility of a subsequent phase 3 trial
Periodo de tiempo: 20 months
  1. Proportion of participants that remained on the SSA cessation arm for the duration of the 20-month study follow up (patient acceptance of SSA cessation).
  2. Rate of recruitment: ability to complete recruitment over the 24-month recruitment period
20 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Measure Quality of life using the European Organisation For Research And Treatment Of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) scales
Periodo de tiempo: 20 months

Responses to the QLQ-C30 scale from 0-100 using EORTC guidelines, with higher scores reflecting better level of functioning.

20 months
Measure Quality of life using the EORTC QLQ-GINET21 scales
Periodo de tiempo: 20 months

Responses to the QLQ-GINET21 scale from 0-100 using EORTC guidelines, with higher scores reflecting more severe symptoms.

20 months
Cost-effectiveness of SSA therapy cessation
Periodo de tiempo: The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.

Access to Medicare and PBS data to asses use of other healthcare providers, diagnostic tests and imaging services funded via public health care systems and use of pharmaceutical services respectively.

The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.
Psycho-oncological impacts of SSA therapy cessation: Decision Regret
Periodo de tiempo: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of Decision Regret Scale from 1 - 5 (1-Strongly Agree, 2-Agree, 3-Neither Agree Nor Disagree, 4-Disagree, 5-Strongly Disagree)

20 months
Psycho-oncological impacts of SSA therapy cessation: Fear of Cancer Progression
Periodo de tiempo: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Fear of Cancer Progression Scale from 1 - 5 (1-Never, 2-Seldom, 3-Sometimes, 4-Often, 5-Very often)

20 months
Psycho-oncological impacts of SSA therapy cessation: Decisional Conflict
Periodo de tiempo: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Decisional Conflict Scale from 0 - 4 (0-Strongly Agree, 1-Agree, 2-Neither Agree Nor Disagree, 3-Disagree, 4-Strongly Disagree)

20 months
Time to commencement of subsequent therapy
Periodo de tiempo: 20 months

Time to commencement of subsequent therapy (e.g re-challenge with PRRT, liver directed therapies, chemotherapy, targeted therapies)

20 months
Overall survival
Periodo de tiempo: 20 months

Estimate the 20-month overall survival rate in patients who cease and who continue SSA.

20 months
Rates of SSA being recommenced over time
Periodo de tiempo: 20 months

Cumulative percentage of SSA recommencement over time.

20 months

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Exploratory analyses
Periodo de tiempo: 20 months

Exploratory analyses including, but not limited to: Define and validate NET tissue and circulating biomarkers with a particular focus on miRNA.

20 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

14 de octubre de 2024

Finalización primaria (Estimado)

1 de septiembre de 2027

Finalización del estudio (Estimado)

1 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

14 de marzo de 2024

Primero enviado que cumplió con los criterios de control de calidad

1 de abril de 2024

Publicado por primera vez (Actual)

3 de abril de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir